`Powerful Medicine'

In "Powerful medicine" (European Business, Feb. 16), the combined revenues of Glaxo Wellcome PLC and SmithKline Beecham PLC would be $26 billion. The combined research and development spending would be $1 billion more than what Novartis spends, not three times as much.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.